The Effect of a Low-fat Spread Enriched With Plant Sterol Esters on the Blood Lipid Profile of Subjects With Established Type 2 Diabetes Mellitus and Subjects at High Risk of Developing Type 2 Diabetes
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Vascular Diseases
- Sponsor
- Unilever R&D
- Enrollment
- 150
- Locations
- 2
- Primary Endpoint
- Change in TG concentrations
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Double-blind, randomised, placebo-controlled, parallel group study with two intervention arms. The study will be conducted in 150 subjects and the primary objective is to show a fasting LDL-cholesterol and triglyceride lowering effect of plant sterols in subjects with established type 2 diabetes mellitus and subjects at high risk of developing type 2 diabetes.
Detailed Description
The main aim of the study is to investigate the effect of plant sterols on fasting triglycerides and LDL-cholesterol concentrations. This study also aims to study the effect of plant sterols on fasting total cholesterol, HDL-cholesterol concentrations and Lipoprotein (a). Furthermore the effects of plant sterols on fasting blood glucose and insulin will be explored. At last, in a sub-group, at end of intervention the acute, chronic and acute upon chronic effect of plant sterols on postprandial blood lipids, glucose and insulin responses during a mixed meal challenge rich in fat and carbohydrates will be explored.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Triglycerides \>150 mg/dL or 1.74 mmol/L
- •LDL-cholesterol: Subjects at high risk for developing T2DM: 115-190 mg/dL or 2.95-4.94 mmol/L. Subjects with established T2DM that are on statins: 85-190 mg/dL or 2.15-4.94 mmol/L.
- •HbA1c: Subjects at high risk for developing T2DM: \<6.50% or ≥ 48 mmol/mol. Subjects with established T2DM: ≤ 8.5% or ≤ 69 mmol/mol.
- •BMI \> 20.0 kg/m2.
Exclusion Criteria
- •Recently (within 1 year) diagnosed with cardiovascular event(s) (stroke, TIA, angina, myocardial infarction, heart failure), systemic inflammatory conditions
- •Use of over-the-counter and prescribed medication which may interfere with study measurements (i.e. ezetimibe, fibrates and Niacin), to be judged by the principal investigator.
- •Currently smoking or being a non-smoker for less than 6 months and reported use of any nicotine containing products in the 6 months prior to screening and/or during the study.
Outcomes
Primary Outcomes
Change in TG concentrations
Time Frame: At baseline (after 2 weeks run-in period) and after 6 weeks intervention
Change in LDL-C
Time Frame: At baseline (after 2 weeks run-in period) and after 6 weeks intervention
Secondary Outcomes
- Change in blood lipids(At baseline (after 2 weeks run-in period) and after 6 weeks intervention)